Aktienanalyse zu Acrivon Therapeutics, Inc. (ACRV)ACRVAcrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Acrivon Therapeutics Inc is currently not a strong buy due to its low price and negative financial indicators, but it has potential upside based on analyst projections. The current price is $1.60, which is significantly below the 52-week high of $3.56, indicating a potential recovery opportunity. However, the company has reported a consistent negative net income, with a Q2 2026 loss of $17.96 million, and an RSI of 39.55 suggests it is nearing oversold territory, which could indicate a price rebound in the future.